<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195883</url>
  </required_header>
  <id_info>
    <org_study_id>09-1051</org_study_id>
    <nct_id>NCT01195883</nct_id>
  </id_info>
  <brief_title>Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity</brief_title>
  <acronym>C-C</acronym>
  <official_title>Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial in which patients having open abdominal surgery are randomized to receive either
      crystalloids or colloids intraoperatively, guided by esophageal Doppler. The investigators
      test the primary hypothesis that goal-directed colloid administration during elective
      abdominal surgery decreases a composite of postoperative complications within 30 days of
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be given 5-7 ml/kg of crystalloid (lactated Ringer's) in the immediate
      preoperative period, which will be followed by 4 ml/kg/h crystalloid for maintenance
      normalized to ideal body weight [Men: Ideal Body Weight (in kilograms) = 52 kg + 1.9 kg for
      every 2.5 cm over 150 cm; Women: Ideal Body Weight (in kilograms) = 49 kg + 1.7 kg for every
      2.5 cm over 150 cm].

      They will then be randomly assigned to additional volume replacement, guided by esophageal
      Doppler, to either lactated Ringer's solution of Voluven starch.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postoperative Morbidity (Major Complications)</measure>
    <time_frame>Postoperative 30-days</time_frame>
    <description>Any of the following major complications: (1) Cardiac (Acute heart failure/Myocardial infarction/Ventricular arrhythmia); (2) pulmonary (embolism/edema/respiratory failure/pneumonia/pleural effusion); (3) gastrointestinal (bowel and surgical anastomosis stricture or anastomotic leak/internal or external fistulas/peritoneal effusions); (4) Renal (requiring dialysis); (5) Infectious (deep or organ space surgical site infection / sepsis); and (6) Coagulation (bleeding).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Morbidity (Minor Complications)</measure>
    <time_frame>Postoperative 30-days</time_frame>
    <description>Any of the following minor complications: (1) unplanned ICU admission; (2) unplanned operation; (3) cardiac (ischemia/non-ventricular arrhythmia/hemodynamic disturbances); (4) pulmonary effusion; (5) deep venous thrombosis; (6) gastrointestinal (effusion/gut paralysis); (7) progressive renal insufficiency; (8) infection (superficial/fever/cystitis or urinary tract infection); and (9) transient neurological injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Complications, 30-day Readmission, and 30-day Death</measure>
    <time_frame>Postoperative 30 days</time_frame>
    <description>A composite of the primary outcome, and readmission and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Acute Kidney Injury</measure>
    <time_frame>Hospitalization</time_frame>
    <description>Preoperative-to-postoperative change in AKIN stage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1102</enrollment>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Crystalloid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactated Ringers solution will be used for fluid replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colloid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crystalloid</intervention_name>
    <description>For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
    <arm_group_label>Crystalloid</arm_group_label>
    <other_name>Ringer's lactate</other_name>
    <other_name>Lactated Ringer's solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloid</intervention_name>
    <description>For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
    <arm_group_label>Colloid</arm_group_label>
    <other_name>Voluven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA Physical Status 1-3

          -  Body Mass Index &lt; 35

          -  Moderate risk elective abdominal surgical procedures scheduled to take ≥ two hours
             done under general anesthesia.

        Exclusion Criteria:

          -  cardiac insufficiency (EF&lt;35%)

          -  coronary disease with angina (NYHA IV)

          -  severe chronic obstructive pulmonary disease

          -  coagulopathies

          -  symptoms of infection or sepsis

          -  renal insufficiency (creatinine clearance &lt;30ml/min or renal replacement therapy)

          -  ASA Physical Status &gt; 3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Kurz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <results_first_submitted>May 17, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2018</results_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IV fluid</keyword>
  <keyword>recovery</keyword>
  <keyword>goal directed fluid replacement</keyword>
  <keyword>improved patient recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crystalloid</title>
          <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Colloid</title>
          <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="553"/>
                <participants group_id="P2" count="549"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="534"/>
                <participants group_id="P2" count="523"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crystalloid</title>
          <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
        </group>
        <group group_id="B2">
          <title>Colloid</title>
          <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="534"/>
            <count group_id="B2" value="523"/>
            <count group_id="B3" value="1057"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="16"/>
                    <measurement group_id="B2" value="52" spread="16"/>
                    <measurement group_id="B3" value="52" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="510"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postoperative Morbidity (Major Complications)</title>
        <description>Any of the following major complications: (1) Cardiac (Acute heart failure/Myocardial infarction/Ventricular arrhythmia); (2) pulmonary (embolism/edema/respiratory failure/pneumonia/pleural effusion); (3) gastrointestinal (bowel and surgical anastomosis stricture or anastomotic leak/internal or external fistulas/peritoneal effusions); (4) Renal (requiring dialysis); (5) Infectious (deep or organ space surgical site infection / sepsis); and (6) Coagulation (bleeding).</description>
        <time_frame>Postoperative 30-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crystalloid</title>
            <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Colloid</title>
            <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Morbidity (Major Complications)</title>
          <description>Any of the following major complications: (1) Cardiac (Acute heart failure/Myocardial infarction/Ventricular arrhythmia); (2) pulmonary (embolism/edema/respiratory failure/pneumonia/pleural effusion); (3) gastrointestinal (bowel and surgical anastomosis stricture or anastomotic leak/internal or external fistulas/peritoneal effusions); (4) Renal (requiring dialysis); (5) Infectious (deep or organ space surgical site infection / sepsis); and (6) Coagulation (bleeding).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>GEE model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Morbidity (Minor Complications)</title>
        <description>Any of the following minor complications: (1) unplanned ICU admission; (2) unplanned operation; (3) cardiac (ischemia/non-ventricular arrhythmia/hemodynamic disturbances); (4) pulmonary effusion; (5) deep venous thrombosis; (6) gastrointestinal (effusion/gut paralysis); (7) progressive renal insufficiency; (8) infection (superficial/fever/cystitis or urinary tract infection); and (9) transient neurological injury.</description>
        <time_frame>Postoperative 30-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crystalloid</title>
            <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Colloid</title>
            <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Morbidity (Minor Complications)</title>
          <description>Any of the following minor complications: (1) unplanned ICU admission; (2) unplanned operation; (3) cardiac (ischemia/non-ventricular arrhythmia/hemodynamic disturbances); (4) pulmonary effusion; (5) deep venous thrombosis; (6) gastrointestinal (effusion/gut paralysis); (7) progressive renal insufficiency; (8) infection (superficial/fever/cystitis or urinary tract infection); and (9) transient neurological injury.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Complications, 30-day Readmission, and 30-day Death</title>
        <description>A composite of the primary outcome, and readmission and death.</description>
        <time_frame>Postoperative 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crystalloid</title>
            <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Colloid</title>
            <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Complications, 30-day Readmission, and 30-day Death</title>
          <description>A composite of the primary outcome, and readmission and death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Acute Kidney Injury</title>
        <description>Preoperative-to-postoperative change in AKIN stage</description>
        <time_frame>Hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crystalloid</title>
            <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Colloid</title>
            <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Acute Kidney Injury</title>
          <description>Preoperative-to-postoperative change in AKIN stage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="527"/>
                <count group_id="O2" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30-days postoperative</time_frame>
      <desc>Adverse Events were monitored/assessed in such a manner that the specific Adverse Event Terms did not be recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Crystalloid</title>
          <description>Lactated Ringers solution will be used for fluid replacement.
Crystalloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.</description>
        </group>
        <group group_id="E2">
          <title>Colloid</title>
          <description>Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
Colloid: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="534"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <description>Acute heart failure
Myocardial infarction
Ventricular arrhythmia</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="534"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Bowel and surgical anastomosis stricture/obstruction or anastomotic leak
Internal or external fistulas
Peritoneal effusions</description>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="534"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections</sub_title>
                <description>Deep or organ/space surgical site infection
Sepsis</description>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="534"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <description>- Requiring dialysis</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <description>Pulmonary embolism
Pulmonary edema
Respiratory failure
Pneumonia
Pulmonary pleural effusion</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <description>Bleeding</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="534"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="534"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <description>Ischemia
Non-ventricular Arrhythmia
Hemodynamic disturbances</description>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="534"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Effusion
Gut paralysis</description>
                <counts group_id="E1" events="103" subjects_affected="103" subjects_at_risk="534"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection
Superficial
Fever
Cystitis or urinary tract Infection</description>
                <counts group_id="E1" events="151" subjects_affected="151" subjects_at_risk="534"/>
                <counts group_id="E2" events="139" subjects_affected="139" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary effusion</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="534"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Minor unplanned operation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="534"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel I. Sessler, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-4900</phone>
      <email>DS@OR.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

